Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Life Sci. 2024 Jan 17:122431. doi: 10.1016/j.lfs.2024.122431. Online ahead of print.
ABSTRACT
Liver disease has become one of the main causes of health issue worldwide. Sirtuin (Sirt) 2 is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, and is expressed in multiple organs including liver, which plays important and complex roles by interacting with various substrates. Physiologically, Sirt2 can improve metabolic homeostasis. Pathologically, Sirt2 can alleviate inflammation, endoplasmic reticulum (ER) stress, promote liver regeneration, maintain iron homeostasis, aggravate fibrogenesis and regulate oxidative stress in liver. In liver diseases, Sirt2 can mitigate fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), but aggravate hepatitis B (HBV) and liver ischemia-reperfusion injury (LIRI). The role of Sirt2 in liver cancer and aging-related liver diseases, however, has not been fully elucidated. In this review, these biological processes regulated by Sirt2 in liver are summarized, which aims to update the function of Sirt2 in liver and to explore the potential role of Sirt2 as a therapeutic target for liver diseases.
PMID:38242495 | DOI:10.1016/j.lfs.2024.122431
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
The role of Sirtuin 2 in liver – An extensive and complex biological process
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy The role and mechanism of SUMO modification in liver disease Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2 Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2 The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD) The gut-liver axis in fatty liver disease: role played by natural products Role of FXR in the development of NAFLD and intervention strategies of small molecules Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease The Beneficial Effect of Brazilian Propolis for Liver Damage through Endoplasmic Reticulum Stress Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action Role of prostaglandin E2 and its receptors in chronic liver disease Role of lactate and lactate metabolism in liver diseases (Review) Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies RNA modifications in the progression of liver diseases: from fatty liver to cancer RNA modifications in the progression of liver diseases: from fatty liver to cancer New nomenclature for fatty liver disease Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024) Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024) Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact Spatial genomics: mapping human steatotic liver disease Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease FGL1 and FGL2: emerging regulators of liver health and disease Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease Aging exacerbates oxidative stress and liver fibrosis in an animal model of Down Syndrome Hepatic lipopolysaccharide binding protein partially uncouples inflammation from fibrosis in MAFLD Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics Angiocrine signaling in sinusoidal homeostasis and liver diseases Fucoidan from Apostichopus japonicus ameliorates alcoholic liver disease by regulating gut-liver axis homeostasis The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis Near-infrared lipid droplets polarity fluorescent probe for early diagnosis of nonalcoholic fatty liver disease Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARalpha Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARalpha SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease Review article: Hepatic steatosis and its associations with acute and chronic liver diseases Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers Hericium erinaceus polysaccharides ameliorate nonalcoholic fatty liver disease via gut microbiota and tryptophan metabolism regulation in an aged laying hen model Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis Key role of interferon regulatory factor 1 (IRF-1) in regulating liver disease: progress and outlook Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1 PIM1 alleviated liver oxidative stress and NAFLD by regulating the NRF2/HO-1/NQO1 pathway Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
Evidence Blueprint
The role of Sirtuin 2 in liver – An extensive and complex biological process
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases Hormone action and liver disease, a complex interplay Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy Emerging roles of RNA-binding proteins in fatty liver disease Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids The role and mechanism of SUMO modification in liver disease Nicotinamide N-methyltransferase and liver diseases Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology Transcription factor EB: A potential integrated network regulator in metabolic-associated cardiac injury What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2 Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2 Fatty liver disease's renaming impacts on drug clinical trials The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD) Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease The gut-liver axis in fatty liver disease: role played by natural products Role of FXR in the development of NAFLD and intervention strategies of small molecules Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease Inflammatory liver diseases and susceptibility to sepsis Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy NLRP3 inflammasome in hepatic diseases: A pharmacological target Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update Macrophage heterogeneity role in NAFLD and NASH disease progression The Beneficial Effect of Brazilian Propolis for Liver Damage through Endoplasmic Reticulum Stress Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action Role of prostaglandin E2 and its receptors in chronic liver disease Akkermansia muciniphila - a Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease Role of lactate and lactate metabolism in liver diseases (Review) Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Corrected and republished from: Metabolic associated liver disease Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities Metabolic dysfunction: The silenced connection with fatty liver disease Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies Extracellular Vesicles and Fatty Liver Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12 Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12 Activating transcription factor (ATF) 6 upregulates cystathionine β synthetase (CBS) expression and hydrogen sulfide (H2S) synthesis to ameliorate liver metabolic damage Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies Review and expert opinion on MAFLD, oxidative stress and multifunctional management Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress